Madrid

• Open-Label Extension of EryDex in A-T (OLE NEAT) Ended
  2024-513618-37-00 5 2024-12-23 Ataxia Telangiectasia (A-T)
• Study to compare drug availability in bloodstream of two oral formulations of mesalazine in healthy volunteers under fed conditions. Ended
  2024-517107-37-00 3 2024-12-20 Chronic idiopathic inflammatory bowel disease
• Bioequivalence clinical trial of two formulations of linagliptin/metformin. Ended
  2024-516081-11-00 2 2024-12-13 Healthy volunteers
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended
  2024-512278-92-00 4 2024-12-09 Pulmonary Arterial Hypertension (PAH)
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors Ended
  2022-502367-37-00 7 2024-11-29 Recurrent glioblastoma multiforme (GBM)
• Phleum pratense and Dactylis glomerata allergen extracts. Determination of the in vivo histamine equivalent prick test units. Ended
  2024-514215-98-00 4 2024-11-26 Allergy to Phleum pratense and Dactylis glomerata.
• A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1) Ended
  2024-514559-13-00 10 2024-11-26 Focal Epilepsy
• Bioequivalence clinical trial of two formulations of linagliptin/metformin Ended
  2024-515076-13-00 2 2024-11-19 Healthy volunteers
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended
  2024-511557-21-00 5 2024-11-14 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults. Ended
  2024-512846-41-00 1 2024-11-12 Respiratory Syncytial Virus Infections
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole Compared to Letrozole Alone in Postmenopausal Wom … Ended
  2024-512848-30-00 4 2024-11-12 HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
• A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended
  2023-507563-19-00 5 2024-11-05 Thyroid eye disease
• Bioequivalence clinical trial of two formulations of loperamide. Ended
  2024-515531-29-00 2 2024-11-04 Healthy volunteers
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509198-22-00 5 2024-10-21 Thyroid Eye Disease (TED)
• A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy Ended
  2024-511998-30-00 5 2024-10-18 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• A study of efgartigimod PH20 SC given by prefilled syringe in adults with thyroid eye disease Ended
  2023-509197-35-00 5 2024-10-17 Thyroid Eye Disease (TED)
• Bioequivalence clinical trial of dapagliflozin 10 mg tablets, after a single oral dose administration to healthy volunteers under fasting co … Ended
  2024-515238-34-00 2 2024-10-10 Diabetes
• Randomized, crossover, two-period, comparative bioavailability study of two ibuprofen (arginate) formulations, administered as solutions in … Ended
  2024-514478-37-00 3 2024-10-04 Healthy volunteers
• Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome Ended
  2023-509638-20-00 4 2024-09-30 Alport Syndrome
• Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-High Dos … Ended
  2023-506000-50-00 4 2024-09-26 Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-H
• An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant e … Ended
  2024-516130-35-00 4 2024-09-26 Multiple myeloma
• Phase 2 study to evaluate the efficacy and safety of GSK3915393 in participants with Idiopathic Pulmonary Fibrosis (IPF) Ended
  2023-509371-16-00 4 2024-09-25 Idiopathic Pulmonary Fibrosis
• A phase 2b dose finding study of RMC-035 in participants undergoing open-chest cardiac surgery Ended
  2024-510658-28-00 4 2024-09-24 Loss of renal function following cardiac surgery

Showing 2,689–2,712 of 3,550 trials